UKRI Chief Executive Sir Mark Walport to step down in 2020
September 13, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UKRI, appointment, pharma
Sir Mark Walport, Chief Executive of UK Research and Innovation (UKRI), the national funding agency responsible for science and research …
General Pharmaceutical Council appoints Laura Fraser as director for Scotland
September 12, 2019The General Pharmaceutical Council has appointed Laura Fraser, former clinical fellow for the Scottish Chief Pharmaceutical Officer as the new …
Roche’s satralizumab succeeds in second positive study in rare CNS disease
September 12, 2019Research and Development NMOSD, Roche, satralizumab
In a second pivotal Phase 3 study of Roche’s satralizumab, the drug showed itself to significantly reduce relapse risk for …
Vertex cystic fibrosis drugs become available in Scotland after NHS rejection
September 12, 2019Sales and Marketing SMC, Vertex, cystic fibrosis
Two potentially life-changing cystic fibrosis drugs are to become available for a potential pool of 400 patients in Scotland just …
Read the September edition of Pharmafocus online now!
September 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, brexit, lung cancer, medicinal cannabis, pharma
The latest monthly edition of Pharmafocus, the September issue, is available to read for free online now!With a new Prime …
UK cancer survival lagging behind other nations
September 12, 2019Research and Development Cancer, british nhs
Cancer survival in the UK is falling behind other high-income nations, despite seeing an overall improvement in survival rates, according …
Novartis’ Mayzent delays time wheelchair dependence by 4 years in secondary progressive multiple sclerosis
September 12, 2019Research and Development ECTRIMS 2019, Mayzent, Novartis, multiple sclerosis, pharma
Novartis has taken the opportunity at the 2019 Congress of The European Committee for Treatment and Research in Multiple Sclerosis …
Former Ergomed CEO appointed as Midatech’s Chief Financial Officer
September 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ergomed, midatech
Immunotherapy-focused pharmaceutical company Midatech Pharma has appointed Stephen Stamp as Chief Financial Officer (CFO) with immediate effect. He will be …
£200m largest ever genetics project launched to combat deadly diseases
September 11, 2019Research and Development
In a huge step forward for public health and the UK’s global leadership in genomics, a £200 million project has …
Decade-long data support Biogen’s Tecfidera in relapsing multiple sclerosis
September 11, 2019Research and Development Biogen, multiple sclerosis, pharma, tecfidera
Biogen has revealed new long-term data for Tecfidera (dimethyl fumarate), reinforcing the benefits of the therapy over a decade-long period …
New aggressive strain of Strep A spreading in UK
September 11, 2019Research and Development Strep A
A new strain of Streptococcus pyogenes called M1UK that is nine times more aggressive is spreading in the UK as …
BMS unveils strong five-year efficacy data for Opdivo in lung cancer
September 11, 2019Research and Development Bristol-Myers Squibb, Cancer, immunotherapy, lung cancer, pharma
Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase …
GlaxoSmithKline acquires Sitari Pharmaceuticals after progress in coeliac disease
September 11, 2019Research and Development, Sales and Marketing Avalon Ventures, GSK, coeliac disease
Avalon Ventures has announced that it has entered into a definitive agreement with GSK for the acquisition of Sitari Pharmaceuticals …
Tony Coles appointed to Pfizer Spinout Cerevel as CEO
September 10, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cerevel, Pfizer, pharma
Cerevel Therapeutics, a pharmaceutical company dedicated to treating neurological diseases, has appointed renowned biotechnology leader Tony Coles as Chief Executive …
Ayala hires AbbVie’s Gary Gordon as new CMO
September 10, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Ayala
AbbVie’s former Vice President of Oncology has moved to Ayala Pharmaceuticals to work as its new Chief Medical Officer (CMO). …
Public Health England calls for action against growing UK opioid crisis threat
September 10, 2019Manufacturing and Production opioid addiction, phe
Public Health England (PHE) have stated that there are far too many people on prescribed drugs that can cause dependence …
MSD’s Keytruda approved for first-line lung cancer use on NHS Scotland
September 10, 2019Manufacturing and Production, Sales and Marketing Cancer, MSD, SMC, Scotland, keytruda, lung cancer, pharma
MSD and lung cancer patients will be celebrating the news that the pharma giant’s immunotherapy Keytruda (pembrolizumab) has been accepted …
Boehringer’s Ofev scores first-of-its-kind FDA approval in rare lung disease
September 10, 2019Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, FDA, US, lungs, ofev, pharma, rare disease
Boehringer Ingelheim’s Ofev (nintedanib) capsules have now secured marketing authorisation in the US, it has emerged, for the treatment of …
SMC gives nod for access to new HIV treatment Dovato
September 10, 2019Manufacturing and Production HIV, SMC
The Scottish Medicines Consortium (SMC) has approved Dovato (dolutegravir/lamivudine) for use on the NHS, allowing treatment of individuals with a …
Axon seeks global partner after positive Phase 2 data for Alzheimer’s vaccine
September 10, 2019Manufacturing and Production, Sales and Marketing Alzheimer's, Alzheimers, Axon
Axon Neuroscience has announced data from its Phase 2 trial ADAMANT for the first-in-class vaccine AADvac1 to slow the progression …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
